{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T14:44:29Z","timestamp":1778337869230,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","award":["MO39447"],"award-info":[{"award-number":["MO39447"]}],"id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019714","name":"Foundation Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019714","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"AstraZeneca UK Ltd Speke","doi-asserted-by":"publisher","award":["ESR-15-11666"],"award-info":[{"award-number":["ESR-15-11666"]}],"id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.esmoop.2022.100507","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T20:28:35Z","timestamp":1654892915000},"page":"100507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Impact of smoking status on the relative efficacy of the EGFR TKI\/angiogenesis inhibitor combination therapy in advanced NSCLC\u2014a systematic review and meta-analysis"],"prefix":"10.1016","volume":"7","author":[{"given":"U.","family":"Dafni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.A.","family":"Soo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Tsourti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Zygoura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Vervita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-Y.","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"De Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Coate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fr\u00fch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.M.S.","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Nadal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Carcereny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Sala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bernab\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Provencio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Cuffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Roschitzki-Voser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Ruepp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.A.","family":"Stahel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100507_bib1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100507_bib2","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.3892\/ol.2016.5287","article-title":"Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer","volume":"12","author":"Hung","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.esmoop.2022.100507_bib3","first-page":"5090","article-title":"Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in\u00a0vivo: a role for altered tumor angiogenesis","volume":"61","author":"Viloria-Petit","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100507_bib4","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100507_bib5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(17)30129-7","article-title":"Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial","volume":"5","author":"Rosell","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.esmoop.2022.100507_bib6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100507_bib7","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100507_bib8","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","article-title":"Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study","volume":"39","author":"Zhou","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2022.100507_bib9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100507_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.annonc.2021.11.010","article-title":"A\u00a0randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial","volume":"33","author":"Soo","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100507_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003583","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"18","author":"Page","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.esmoop.2022.100507_bib12","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"10.1016\/j.esmoop.2022.100507_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A\u00a0basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.esmoop.2022.100507_bib14","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.esmoop.2022.100507_bib15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.esmoop.2022.100507_bib16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"key":"10.1016\/j.esmoop.2022.100507_bib17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.cllc.2016.04.001","article-title":"BEVERLY: rationale and design of a randomized open-label phase III trial comparing bevacizumab plus erlotinib versus erlotinib alone as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small-cell lung cancer","volume":"17","author":"Gridelli","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.esmoop.2022.100507_bib18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lungcan.2020.11.020","article-title":"Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: survival follow-up results of the randomized JO25567 study","volume":"151","author":"Yamamoto","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2022.100507_bib19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2213-2600(21)00166-1","article-title":"Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"10","author":"Kawashima","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.esmoop.2022.100507_bib20","doi-asserted-by":"crossref","first-page":"S1322","DOI":"10.1016\/j.annonc.2021.08.2123","article-title":"LBA44 Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study","volume":"32","author":"Kenmotsu","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100507_bib21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamaoncol.2020.6758","volume":"7","author":"Akamatsu","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2022.100507_bib22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2017.11.005","article-title":"A\u00a0comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer","volume":"114","author":"Tu","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2022.100507_bib23","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100507_bib24","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jtho.2020.12.002","article-title":"Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non Exon 20 insertions, EGFR mutations","volume":"16","author":"Passaro","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.esmoop.2022.100507_bib25","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.annonc.2022.02.225","article-title":"Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)","volume":"33","author":"Janning","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100507_bib26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41571-021-00558-1","article-title":"EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment","volume":"19","author":"Friedlaender","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100507_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-13-0539","article-title":"Smoking, p53 mutation, and lung cancer","volume":"12","author":"Gibbons","year":"2014","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100507_bib28","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1158\/1078-0432.CCR-21-0273","article-title":"RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non\u2013small cell lung cancer","volume":"27","author":"Nakagawa","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100507_bib29","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1158\/0008-5472.CAN-14-2305","article-title":"VEGF-A expression correlates with TP53 mutations in non\u2013small cell lung cancer: implications for antiangiogenesis therapy","volume":"75","author":"Schwaederl\u00e9","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100507_bib30","doi-asserted-by":"crossref","first-page":"705","DOI":"10.18632\/oncotarget.974","article-title":"P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy","volume":"4","author":"Said","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2022.100507_bib31","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1158\/1535-7163.MCT-16-0196","article-title":"TP53 alterations correlate with response to VEGF\/VEGFR inhibitors: implications for targeted therapeutics","volume":"15","author":"Wheler","year":"2016","journal-title":"Mol Cancer Ther"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922001272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922001272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:28:08Z","timestamp":1761856088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922001272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2059702922001272"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100507","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of smoking status on the relative efficacy of the EGFR TKI\/angiogenesis inhibitor combination therapy in advanced NSCLC\u2014a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100507","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100507"}}